CBR1 Human
Description
CBR1 is purified by proprietary chromatographic techniques.
Product Specs
Carbonyl reductase 1 (CBR1) is a monomeric NADPH-dependent oxidoreductase found in various human tissues. It exhibits broad substrate specificity, primarily targeting carbonyl compounds. CBR1 plays a crucial role in detoxifying toxic environmental quinones and metabolizing pharmacologically significant substrates. Notably, it facilitates the conversion of prostaglandin E2 to prostaglandin F2-alpha.
MSSGIHVALV TGGNKGIGLA IVRDLCRLFS GDVVLTARDV TRGQAAVQQL QAEGLSPRFH QLDIDDLQSI RALRDFLRKE YGGLDVLVNN AGIAFKVADP TPFHIQAEVT MKTNFFGTRD VCTELLPLIK PQGRVVNVSS IMSVRALKSC SPELQQKFRS ETITEEELVG LMNKFVEDTK KGVHQKEGWP SSAYGVTKIG VTVLSRIHAR KLSEQRKGDK ILLNACCPGW VRTDMAGPKA TKSPEEGAET PVYLALLPPD AEGPHGQFVS EKRVEQW.
Product Science Overview
Carbonyl Reductase-1 (CBR1) is an enzyme that belongs to the short-chain dehydrogenases/reductases (SDR) family. This enzyme is widely distributed in human tissues and plays a crucial role in the metabolism of various carbonyl compounds, including quinones, prostaglandins, and xenobiotics . CBR1 is known for its NADPH-dependent oxidoreductase activity, which allows it to reduce carbonyl groups to their corresponding alcohols .
CBR1 is involved in several important biological processes. It metabolizes toxic environmental quinones and pharmacologically relevant substrates, such as the anticancer drug doxorubicin . Additionally, CBR1 converts prostaglandin E2 to prostaglandin F2-alpha, which is significant in various physiological processes . The enzyme also plays a protective role in oxidative stress, neurodegeneration, and apoptosis by inactivating lipid aldehydes during oxidative stress in cells .
CBR1 has been studied for its role in protecting cells against oxidative stress and its potential therapeutic applications. For instance, it has been identified as a target to improve the effect of radiotherapy on head and neck squamous cell carcinoma (HNSCC) . Research has shown that inhibiting CBR1 can enhance radiosensitivity in HNSCC cells, leading to better treatment outcomes . This makes CBR1 a promising target for developing new therapeutic strategies for cancer treatment.
